Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in several key investor conferences in March 2025.
The company will engage in fireside chats at the following events:
- TD Cowen 45th Annual Healthcare Conference in Boston (March 5, 9:10 a.m. ET)
- Leerink Partners Global Biopharma Conference in Miami (March 11, 8:00 a.m. ET)
- Jefferies Biotech on the Bay Summit in Miami (March 12, one-on-one meetings)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (March 27, 10:30 a.m. ET)
Live webcasts will be accessible through the Investors section of Kymera's website, with replays available after the events.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced it will release its fourth quarter and full year 2024 financial results on February 27, 2025. The company will host a video conference call at 8:30 a.m. ET on the same day. Investors can access the video call through registration or view the livestreamed webcast in the 'News and Events' section of Kymera's website. A replay of the webcast will be available after the event.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its participation in two major investor conferences in February 2025.
The company will engage in fireside chats at the Guggenheim SMID Cap Biotechnology Conference in New York on February 6 at 10:00 a.m. ET, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on February 11 at 11:20 a.m. ET.
Live webcasts of both presentations will be accessible through the Investors section under "News and Events" on Kymera's website (www.kymeratx.com). Recordings will be archived and available for viewing after the events.
Kymera Therapeutics (NASDAQ: KYMR) has outlined its key objectives for 2025, focusing on advancing its oral immunology programs. The company's lead candidate, KT-621, a STAT6 degrader, is in Phase 1 trials with data expected in Q2 2025, followed by Phase 1b trials in atopic dermatitis. Their KT-295 TYK2 degrader will advance to Phase 1 testing in Q2 2025, while KT-474/SAR444656 Phase 2b studies in hidradenitis suppurativa and atopic dermatitis are ongoing.
The company plans to disclose a novel oral immunology program in H1 2025. With an estimated $850 million in cash, Kymera has runway into mid-2027. Their strategy focuses on developing oral drugs with biologics-like activity for treating inflammatory diseases, particularly targeting conditions like atopic dermatitis, asthma, and other Th2-driven diseases affecting over 130 million patients globally.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET in San Francisco, California.
The company's Founder, President and CEO, Nello Mainolfi, PhD, will present an overview of Kymera's progress and outline anticipated milestones for 2025. Interested parties can access a live webcast of the presentation and Q&A session through the 'News and Events' section of Kymera's investor relations website. The presentation recording will be archived and available for later viewing.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in two major investor conferences this December. The company will engage in fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:00 p.m. ET, and the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 4:15 p.m. ET. Live webcasts will be available on Kymera's website under the Investors section, with replays accessible after the events.
Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in several major healthcare investor conferences this November. The company will engage in fireside chats at the Guggenheim Inaugural Healthcare Innovation Conference in Boston, Stifel 2024 Healthcare Conference in New York, Wolfe Research Healthcare Conference in New York, and Jefferies London Healthcare Conference in London. Additionally, they will attend the J.P. Morgan Equity Opportunities Forum in Miami for one-on-one meetings. Live webcasts of the presentations will be available on the company's website under the Investors section, with replays accessible after the events.
Kymera Therapeutics (NASDAQ: KYMR) reported Q3 2024 financial results and business updates. Key developments include FDA clearance and Phase 1 trial initiation for KT-621 (STAT6), with data expected in H1 2025. Sanofi is expanding KT-474 Phase 2 trials in HS and AD to Phase 2b studies. The company nominated KT-295 as its TYK2 degrader development candidate for Phase 1 trials in H1 2025.
The company will shift focus from oncology to immunology, seeking partners for oncology programs beyond Phase 1. Financial results show $3.7M in collaboration revenues, $62.5M net loss, and $911M in cash, providing runway into mid-2027.
Kymera Therapeutics (NASDAQ: KYMR) has initiated dosing in a Phase 1 clinical trial for KT-621, the first-ever oral STAT6 degrader to enter clinical development. The trial evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers through single and multiple ascending dose cohorts. KT-621 demonstrated dupilumab-like activity in preclinical models for treating TH2 immuno-inflammatory diseases, with potential as a convenient once-daily oral alternative to injectable treatments. Phase 1 data is expected in the first half of 2025.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has scheduled its third quarter 2024 financial results announcement for October 31, 2024. The company will host a conference call at 8:30 a.m. ET on the same day. Investors can join via phone at +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International). A live webcast will be available on the company's website under the Investors section, with a replay available after the event.